Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)
ID: 356624Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356624

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-050.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)." This initiative aims to support the rigorous analytical validation of methods used to measure biomarkers for neurological and neuromuscular disorders, which are critical for clinical trials and practice. Applicants are required to demonstrate the unmet need for the biomarker(s) and measurement methods, detailing activities such as optimizing accuracy, precision, and establishing quality control procedures across multiple sites. The submission portal opens on January 21, 2025, with applications due by June 22, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-050.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-050.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a funding opportunity to support the analytical validation of biomarkers for neurological and neuromuscular disorders. The funding, titled "Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)," aims to rigorously assess measurement methods for biomarkers that could be used in clinical trials or practice. Applicants are expected to demonstrate the clinical and research needs for the biomarker(s) and validation methods, ensuring accuracy and reliability. Key activities include establishing testing sensitivity, specificity, and precision, especially across multiple testing sites. Applications must detail milestones, convey collaborative efforts among diverse scientific and clinical teams, and include a 'Plan for Enhancing Diverse Perspectives' to foster inclusivity. The submission portal is open from January 21, 2025, with awards contingent upon available funding and selected applications being subjected to peer review. The NIH emphasizes that proposals need to address an unmet medical need, display a substantial biological rationale, and clearly outline plans for evaluating the performance and clinical utility of the proposed biomarkers.
    Similar Opportunities
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)." This initiative aims to support the clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders, focusing on establishing their clinical sensitivity and specificity in accordance with FDA guidelines. The program is particularly significant as it seeks to enhance public health outcomes by facilitating the implementation of validated biomarkers in clinical settings, thereby addressing critical healthcare needs in these areas. Interested applicants should note that the application period opens on January 21, 2025, and closes on June 22, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-055.html.
    Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through a Cooperative Agreement for the analytical validation of candidate biomarkers aimed at neurological and neuromuscular disorders. This initiative seeks to rigorously validate analytical methods for biomarker measurements, ensuring their accuracy and reproducibility in alignment with FDA guidelines, with a focus on addressing unmet clinical needs and potential applications in clinical trials. The program encourages diverse research teams and collaboration, emphasizing the importance of inclusivity in the research process, and applications are due by June 22, 2026, with funding available for a maximum period of four years. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)" under Funding Opportunity Number PAR-24-097. This initiative aims to clinically validate candidate biomarkers for neurological diseases, focusing on establishing their clinical sensitivity and specificity, provided that preliminary conditions such as detection method development are met. The program emphasizes the importance of multidisciplinary collaborations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams. Interested applicants must submit their proposals by February 22, 2024, with project durations capped at five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-097.html.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the clinical validation of candidate biomarkers for neurological and neuromuscular disorders through the U44 Cooperative Agreement mechanism. This initiative aims to rigorously validate biomarkers that have already been identified and for which detection methods have been developed, ensuring compliance with FDA guidelines to establish their clinical sensitivity and specificity. This program is crucial for advancing therapeutic development in the field of brain health, with funding potentially reaching $700,000 for Phase I and $1.5 million for Phase II projects. Interested applicants must adhere to specific submission guidelines and deadlines, with the application closing on June 22, 2026. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-096.html.
    Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders," aimed at supporting the rigorous analytical validation of biomarker measurement methods for neurological diseases. This initiative seeks proposals from small businesses to conduct analytical validation, requiring applicants to justify their chosen biomarkers, outline contexts of use, and include a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity in research. Grants are available under U44 Small Business Innovation Research (SBIR) cooperative agreements, with funding amounts up to $700,000 annually for Phase I and up to $1.5 million for Phase II, and applications are due by June 25, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-098.html.
    Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders through a phased grant mechanism (R61/R33). This funding opportunity aims to enhance the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and improve clinical care decisions. The initiative emphasizes the importance of multidisciplinary collaboration and requires applicants to validate biomarkers in a phased approach, with the R61 phase focusing on proof of concept studies and the R33 phase on preliminary clinical validation. Interested applicants should note that the application deadline is January 7, 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-024.html.
    Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)." This initiative aims to promote the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and their application in clinical practice, focusing on both animal studies and preliminary human evaluations. The funding is structured as a phased R61/R33 award, where the R61 phase emphasizes proof-of-concept studies using human samples, while the R33 phase focuses on clinical validation for specified uses. Interested applicants, including various educational and community organizations, must submit their proposals by May 7, 2025, and can find additional details and application guidelines at the provided NIH link. For inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD)?(U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Analytical and Clinical Validation of Biomarkers for Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD)" (PAR-23-258), aimed at supporting the validation of biomarkers to enhance therapy development and clinical practices. This initiative seeks applications that focus on achieving rigorous analytical and clinical validation of biomarkers, aligning with the standards set by the FDA’s Biomarker Qualification Program. The program is crucial for advancing research strategies that validate candidate biomarkers across diverse populations, thereby facilitating their use in clinical trials and medical product development. Interested applicants, including various educational and community organizations, must submit their proposals by March 6, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants," aimed at accelerating the clinical validation of biomarker assays for cancer detection, diagnosis, prognosis, and treatment response. This initiative encourages multidisciplinary collaboration among researchers, clinicians, and statisticians, focusing on assays that have nearly completed analytical validation and utilize human specimens. The funding amount is capped at $150,000 per year for a maximum duration of three years, with application deadlines starting from January 14, 2025, and concluding on October 15, 2026. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.